End-point Dilution Assay

The end-point dilution assay (EPDA) is useful for a variety of assays. A 96-well plate EPDA may be used to replace the plaque assay and plaque purification as a method for either determining viral titer or identifying and purifying recombinant virus. A modified 12-well plate EPDA can be used as a routine method for determining viral titer; it is useful for estimating the efficiency of the initial co-transfection, identifying infected cells, approximating viral titers, and amplifying viral titer. In the 12-well EPDA, individual wells containing equal amounts of insect cells are inoculated with 100, 10, 1 or 0 µl aliquots of the original transfection supernatant, wild-type virus, or recombinant XylE positive control viral supernatant. A visual comparison between cells in wells inoculated with 100, 10, 1 and 0 µl is used to estimate the viral titer.

For example, if cells receiving 100 µl of the initial co-transfection supernatant look infected in the EPDA, but cells receiving 10, 1 and 0 µl do not, then it is likely that the viral titer is low and should be amplified to produce a high titer stock. If wells receiving 100 µl of the original co-transfection supernatant look similar to those receiving 0 µl, it is likely that the original co-transfection did not result in a significant viral titer and must be repeated. When assaying the efficiency of a co-transfection or estimating the titer of a virus stock, if the EPDA shows a 10 fold decrease in the number of infected cells between dilutions, amplify the virus once or twice more to generate a high titer stock for protein production. However, if all three wells (100, 10, 1 µl) show equal signs of infection, the viral titer is high, ~ 2 x 108 plaque-forming units (pfu) /ml. High titer recombinant virus stocks are used for infection of cells at optimal multiplicity of infection (MOI = # of virus / # of cells) resulting in maximum protein production.

If the EPDA is used as an amplification step to generate a high titer stock, cross contamination between wells containing different viruses, eg., the highly infectious wild-type virus used as a positive control, can be avoided by using separate 12 well plates.

EPDA controls are recommended. The recombinant virus from a pVL1392-XylE transfection is a particularly useful positive control. Infected cells producing the the XylE protein turn yellow in the presence of catechol and are easily identifiable.

Protocol

  1. Dilute log-phase Sf9 cells (with greater than 98% viability) to 1 x 105 cells /ml with fresh TNM-FH medium. Seed 1 x 105 Sf9 cells per well on a 12-well plate (BD Falcon™, Cat. No. 353043). Allow cells to attach firmly, approximately 10 min. Confirm 30% confluency by visualization on a light microscope. Replace medium with 1 ml fresh TNM-FH.
  2. Add 100, 10, 1 and 0 µl of the recombinant virus supernatant obtained 5 days after the start of co-transfection (or other virus stock), to separate wells. Do the same for the positive control, e.g., pVL1392-XylE supernatant.
  3. Incubate the cells at 27°C for three days. Examine the cells for signs of infection.
  4. A successful transfection should result in uniformly large infected cells in the 100, 10, and 1 µl experimental wells. The cells in the 0 µl control wells should not look infected because they were not inoculated with virus.
  5. If only the 100 µl and 10 µl wells seem to have infected cells and the 1 µl well looks more like the control, the titer of your virus supernatant is low. Amplify the virus an additional time before proceeding with protein production.
  • Protein production can be analyzed by western blot analysis (if antibodies are available) or by Coomassie blue-stained SDS-PAGE gel by harvesting cells from the 100 µl well and lysing in appropriate lysing buffer.
  • The virus supernatant from the 100 µl well may be kept as the first viral amplification stock, however care should be taken to avoid cross-contamination between wells containing different virus.
  • To further purify the virus population, a plaque assay purification of the co-transfection supernatant may be performed using the approximate titer obtained from the EPDA.

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.